HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-gamma and pentavalent antimonial compounds.

Abstract
In an open trial, longer courses of pentavalent antimonials (Sbv) at sub-optimal doses (10 mg/kg body weight), in association with recombinant human interferon-gamma (IFN-gamma) (100 micrograms/m2 of body surface area) were administered, by daily intramuscular injections, to 13 patients with diagnoses of cutaneous or mucocutaneous leishmaniasis unresponsive to Sbv. Four patients presented with large skin ulcers, and 9 had mucosal involvement as the main manifestation, the latter affecting the nose (3 cases), nose and septum (2 cases), nose and oral cavity (1 case), and nose, pharynx and larynx (3 cases). Except for one case with severe involvement of the upper respiratory tract, the lesions were fully resolved by the end of therapy (mean duration 40 +/- 12 [SD] d, range 30-60 d) in the 11 patients who completed therapy. The main side effects were headache and fever (7 cases), together with leucopenia and eosinophilia (4 cases). It is concluded that combined administration of low doses of Sbv plus IFN-gamma may provide a novel therapeutic approach for the treatment of antimony-resistant cutaneous or mucocutaneous leishmaniasis. The possible mechanisms by which IFN-gamma contributes to resolution of the disease are discussed.
AuthorsE Falcoff, N J Taranto, C E Remondegui, J P Dedet, L M Canini, C M Ripoll, L Dimier-David, F Vargas, L A Giménez, J G Bernabó
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene (Trans R Soc Trop Med Hyg) 1994 Jan-Feb Vol. 88 Issue 1 Pg. 95-7 ISSN: 0035-9203 [Print] England
PMID8154019 (Publication Type: Journal Article)
Chemical References
  • Recombinant Proteins
  • Interferon-gamma
  • Antimony
Topics
  • Adolescent
  • Adult
  • Antimony (adverse effects, therapeutic use)
  • Combined Modality Therapy
  • Drug Resistance
  • Female
  • Follow-Up Studies
  • Humans
  • Interferon-gamma (adverse effects, therapeutic use)
  • Leishmaniasis, Cutaneous (therapy)
  • Leishmaniasis, Mucocutaneous (therapy)
  • Male
  • Middle Aged
  • Recombinant Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: